Key Insights

Highlights

Success Rate

94% trial completion (above average)

Published Results

63 trials with published results (25%)

Research Maturity

166 completed trials (66% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.0%

10 terminated out of 252 trials

Success Rate

94.3%

+7.7% vs benchmark

Late-Stage Pipeline

21%

54 trials in Phase 3/4

Results Transparency

38%

63 of 166 completed with results

Key Signals

63 with results94% success

Data Visualizations

Phase Distribution

202Total
Not Applicable (44)
Early P 1 (4)
P 1 (47)
P 2 (53)
P 3 (31)
P 4 (23)

Trial Status

Completed166
Unknown31
Recruiting20
Active Not Recruiting11
Terminated10
Not Yet Recruiting6

Trial Success Rate

94.3%

Benchmark: 86.6%

Based on 166 completed trials

Clinical Trials (252)

Showing 20 of 20 trials
NCT06924658Phase 2RecruitingPrimary

Metformin in Safety and Efficacy in Gouty Patients

NCT07280156Phase 2RecruitingPrimary

A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)

NCT07089875Phase 3RecruitingPrimary

A Study of Dotinurad Versus Allopurinol in Participants With Gout

NCT06846515Phase 3CompletedPrimary

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)

NCT07535034Phase 2RecruitingPrimary

A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants

NCT07834840Not ApplicableEnrolling By Invitation

Evaluation of the Impact of Dietary Education and Intervention on Gout Patients Receiving Urate-Lowering Therapy

NCT04031469Suspended

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT01336686Phase 2Completed

Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout

NCT02252835Phase 2CompletedPrimary

Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout

NCT07824895Phase 4Not Yet RecruitingPrimary

Mazdutide for Weight Management and Gout in Adults With Obesity

NCT06995339Phase 2CompletedPrimary

Comparative Clinical and Biochemical Study Evaluating the Effectiveness of Metformin Versus Febuxostat on Gouty Obese Non-Diabetic Patients

NCT06229145Phase 4CompletedPrimary

A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

NCT05507723Not ApplicableActive Not RecruitingPrimary

Tight Control of Gouty Arthritis Compared to Usual Care

NCT07546643Active Not Recruiting

Long-Term Risk of Gout in Living Kidney Donors

NCT07414394Phase 3Active Not RecruitingPrimary

Tigulixostat (IBI128) vs Febuxostat in Gout

NCT06439602Phase 3CompletedPrimary

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)

NCT07784049Not Yet RecruitingPrimary

The Correlation Between Sodium Urate (MSU) Deposition and Coronary Atherosclerosis in Patients With Foot Gout

NCT07752810Phase 1CompletedPrimary

Study of Safety, PK, and Efficacy of Multiple Ascending Doses of HZBio1 in Patients With Gout

NCT05499312Phase 2CompletedPrimary

An Innovative Chinese Herbal Formula for the Treatment of Gout

NCT05665699Phase 2CompletedPrimary

Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout

Scroll to load more

Research Network

Activity Timeline